**FOI Ref: 6489**

**Category(ies): Clinical - Drugs**

**Subject: Use of Biologic Medications to Treat Dermatological Conditions**

**Date Received: 11/07/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I am analysing the usage of new biologic medications for the treatment of dermatological conditions. I would greatly appreciate if you could answer the following question. | |
| How many patients were treated in June 2022 (or latest available month) by the dermatology department with the following drugs:   * Abrocitinib (Cibinqo) * Baricitinib (Olumiant) * Bimekizumab (Bimzelx) * Brodalumab (Kyntheum) * Dupilumab (Dupixent) * Ixekizumab (Taltz) * Risankizumab (Skyrizi) * Guselkumab (Tremfya) * Secukinumab (Cosentyx) * Tildrakizumab (Ilumetri) * Tralokinumab (Adtralza) * Upadacitinib (Rinvoq) * Ustekinumab (Stelara) | * 0 * 1 * 0 * 2 * 29 * 3 * 6 * 22 * 19 * 0 * 0 * 0 * 11 |